Sio Capital Management Upped Its Adamis Pharmaceuticals (ADMP) Position, Prima Biomed Limited Ads (PBMD) Shorts Down By 2.04%

June 20, 2017 - By Vivian Park

Prima Biomed Limited Ads (NASDAQ:PBMD) had a decrease of 2.04% in short interest. PBMD’s SI was 149,100 shares in June as released by FINRA. Its down 2.04% from 152,200 shares previously. With 22,300 avg volume, 7 days are for Prima Biomed Limited Ads (NASDAQ:PBMD)’s short sellers to cover PBMD’s short positions. The SI to Prima Biomed Limited Ads’s float is 0.78%. About 4,466 shares traded. Prima BioMed Ltd (ADR) (NASDAQ:PBMD) has declined 26.19% since June 20, 2016 and is downtrending. It has underperformed by 42.89% the S&P500.

Sio Capital Management Llc increased Adamis Pharmaceuticals Corp (ADMP) stake by 57.95% reported in 2016Q4 SEC filing. Sio Capital Management Llc acquired 385,608 shares as Adamis Pharmaceuticals Corp (ADMP)’s stock rose 11.43%. The Sio Capital Management Llc holds 1.05M shares with $3.31 million value, up from 665,455 last quarter. Adamis Pharmaceuticals Corp now has $132.46M valuation. The stock declined 3.92% or $0.2 reaching $4.9 on the news. About 1.38M shares traded. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has declined 52.09% since June 20, 2016 and is downtrending. It has underperformed by 68.79% the S&P500.

Sio Capital Management Llc decreased Amgen Inc (NASDAQ:AMGN) stake by 74,870 shares to 16,430 valued at $2.40M in 2016Q4. It also reduced Amgen Inc (Put) (NASDAQ:AMGN) stake by 61,300 shares and now owns 30,000 shares. Koninklijke Philips Nv (Call) (NYSE:PHG) was reduced too.

Among 2 analysts covering Adamis Pharma (NASDAQ:ADMP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 3 analyst reports since December 1, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group with “Buy” on Thursday, July 21. The company was initiated on Tuesday, December 1 by Maxim Group.

Among 5 analysts covering Prima Biomed (NASDAQ:PBMD), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Prima Biomed had 5 analyst reports since October 14, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, December 30 by Roth Capital. The firm has “Outperform” rating by FBR Capital given on Thursday, December 3. As per Thursday, May 12, the company rating was maintained by Maxim Group. TH Capital initiated Prima BioMed Ltd (ADR) (NASDAQ:PBMD) rating on Thursday, December 31. TH Capital has “Buy” rating and $6 target. The rating was initiated by H.C. Wainwright on Wednesday, October 14 with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: